Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.

Roche DJ, Ray LA, Yardley MM, King AC.

Curr Addict Rep. 2016 Mar;3(1):125-137. Epub 2016 Feb 3.

PMID:
27162709
2.

Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence.

Burke MV, Hays JT, Ebbert JO.

Patient Prefer Adherence. 2016 Apr 1;10:435-41. doi: 10.2147/PPA.S83469. eCollection 2016. Review.

3.

Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ.

J Am Heart Assoc. 2016 Feb 22;5(2). pii: e002849. doi: 10.1161/JAHA.115.002849.

4.

Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

Van Skike CE, Maggio SE, Reynolds AR, Casey EM, Bardo MT, Dwoskin LP, Prendergast MA, Nixon K.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:269-87. doi: 10.1016/j.pnpbp.2015.11.004. Epub 2015 Nov 12.

PMID:
26582145
5.

Evaluation of the cardiovascular effects of varenicline in rats.

Selçuk EB, Sungu M, Parlakpinar H, Ermiş N, Taslıdere E, Vardı N, Yalçınsoy M, Sagır M, Polat A, Karatas M, Kayhan-Tetik B.

Drug Des Devel Ther. 2015 Oct 22;9:5705-17. doi: 10.2147/DDDT.S92268. eCollection 2015.

6.

Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers.

Yardley MM, Mirbaba MM, Ray LA.

CNS Drugs. 2015 Oct;29(10):833-45. doi: 10.1007/s40263-015-0284-5.

PMID:
26507831
7.

The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study.

Froeliger B, McConnell PA, Stankeviciute N, McClure EA, Kalivas PW, Gray KM.

Drug Alcohol Depend. 2015 Nov 1;156:234-42. doi: 10.1016/j.drugalcdep.2015.09.021. Epub 2015 Sep 26.

PMID:
26454838
8.

Resting-state functional connectivity and nicotine addiction: prospects for biomarker development.

Fedota JR, Stein EA.

Ann N Y Acad Sci. 2015 Sep;1349:64-82. doi: 10.1111/nyas.12882. Review.

PMID:
26348486
9.

Paecilomycies japonica reduces repeated nicotine-induced neuronal and behavioral activation in rats.

Ye M, Lee H, Bae H, Hahm DH, Lee HJ, Shim I.

BMC Complement Altern Med. 2015 Jul 14;15:227. doi: 10.1186/s12906-015-0739-8.

10.

Negative affective states and cognitive impairments in nicotine dependence.

Hall FS, Der-Avakian A, Gould TJ, Markou A, Shoaib M, Young JW.

Neurosci Biobehav Rev. 2015 Nov;58:168-85. doi: 10.1016/j.neubiorev.2015.06.004. Epub 2015 Jun 6. Review.

PMID:
26054790
11.

Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.

Roche DJ, Bujarski S, Hartwell E, Green R, Ray LA.

Pharmacol Biochem Behav. 2015 Jul;134:92-8. doi: 10.1016/j.pbb.2015.04.013. Epub 2015 Apr 28.

PMID:
25933795
12.

Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.

Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D.

BMJ. 2015 Mar 12;350:h1109. doi: 10.1136/bmj.h1109. Review.

13.

Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers.

Fedota JR, Sutherland MT, Salmeron BJ, Ross TJ, Hong LE, Stein EA.

Neuropsychopharmacology. 2015 Jul;40(8):2038-46. doi: 10.1038/npp.2015.54. Epub 2015 Mar 6.

PMID:
25742873
14.

Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states.

Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS.

Neuropharmacology. 2015 Sep;96(Pt B):235-43. doi: 10.1016/j.neuropharm.2014.12.028. Epub 2015 Jan 9. Review.

PMID:
25582289
15.

Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation.

Ramon JM, Morchon S, Baena A, Masuet-Aumatell C.

BMC Med. 2014 Oct 8;12:172. doi: 10.1186/s12916-014-0172-8.

16.

Smoking, chronic wound healing, and implications for evidence-based practice.

McDaniel JC, Browning KK.

J Wound Ostomy Continence Nurs. 2014 Sep-Oct;41(5):415-23; quiz E1-2. doi: 10.1097/WON.0000000000000057.

17.

Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.

Ravva P, Gastonguay MR, Faessel HM, Lee TC, Niaura R.

Nicotine Tob Res. 2015 Jan;17(1):106-13. doi: 10.1093/ntr/ntu154. Epub 2014 Aug 21.

18.

Organic cation transporter variation and response to smoking cessation therapies.

Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, Edlund CK, Kwok PY, McClure JB, Kim RB, Hall SM, Tyndale RF, Baker TB, Benowitz NL, Swan GE.

Nicotine Tob Res. 2014 Dec;16(12):1638-46. doi: 10.1093/ntr/ntu161. Epub 2014 Aug 20.

19.

An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.

McClure EA, Baker NL, Gipson CD, Carpenter MJ, Roper AP, Froeliger BE, Kalivas PW, Gray KM.

Am J Drug Alcohol Abuse. 2015 Jan;41(1):52-6. doi: 10.3109/00952990.2014.933839. Epub 2014 Jul 25.

20.

Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.

Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED.

Am J Drug Alcohol Abuse. 2015 Jan;41(1):35-44. doi: 10.3109/00952990.2014.927881. Epub 2014 Jun 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk